Jason is a partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. He was the founding CEO and is the chairman of Dyne Therapeutics (NASDAQ: DYN), Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals, and previously Disarm Therapeutics (acquired by Eli Lilly). He was also on the boards of Replimune (NASDAQ: REPL) and Third Harmonic Bio (NASDAQ: THRD).